Upadacitinib Safety Similar to Other Jakinibs for RA

The clinical relevance of creatinine phosphokinase elevations is also uncertain, but it may be relevant to measure the level this enzyme before and some weeks after initiation of treatment, says Dr. Tore Kvien, a professor emeritus and senior researcher at the University of Oslo and the department of rheumatology at Diakonhjemmet Hospital, Oslo, Norway.

“Overall, upadacitinib represents an important treatment alternative for patients with RA, but patients and clinicians should be aware of potential adverse events and take this into account when prescribing upadacitinib and monitoring patients during follow-up,” Dr. Kvien, who wasn’t involved in the study, says by email.

Reference

Cohen SB, van Vollenhoven RF, Winthrop KL, et al. Safety profile of upadacitinib in rheumatoid arthritis: Integrated analysis from the SELECT phase III clinical programme. Ann Rheum Dis. 2020 Oct 28;annrheumdis-2020-218510. Online ahead of print.

As treatments for psoriatic arthritis (PsA) emerge, a clinical trial comparing the Janus kinase (JAK) inhibitor upadacitinib and the tumor necrosis factor (TNF) inhibitor adalimumab provided some new insights. Published earlier this year in The New England Journal of Medicine, the SELECT-PsA 1, double-blind, phase 3 trial found that a 30 mg dose of upadacitinib…

In phase 3 clinical trial, upadacitnib proved superior to placebo and adalimumab in improving the signs and symptoms of RA in patients on stable background methotrexate.

PHILADELPHIA—Selecting my top 10 picks for abstracts in psoriatic arthritis (PsA) at the ACR Convergence 2022 meeting was not easy because there was a great deal to review and learn from the 139 abstracts submitted to the meeting. I focused first and foremost on advances in therapeutics that encompassed both new and approved therapeutics, novel…

The FDA has approved upadacitinib for the treatment of non-radiographic axial spondyloarthritis (nr-axSpA) based on a short-term study that demonstrated improved pain, function and other symptoms of nr-axSpA in patients with active disease.

Trial Pits Upadacitinib vs. Adalimumab for Psoriatic Arthritis

Upadacitnib for RA: Researchers Compared Upadacitinib with Placebo & Adalimumab in Patients with RA & an Inadequate Response to Methotrexate

Psoriatic Arthritis: Advances in Therapeutics, Imaging & More Presented at ACR Convergence 2022

FDA Approves Upadacitinib for Non-Radiographic Axial Spondyloarthritis

Related Articles